Advertisement
UK markets close in 3 hours 9 minutes
  • FTSE 100

    8,229.70
    -18.09 (-0.22%)
     
  • FTSE 250

    20,339.66
    -23.77 (-0.12%)
     
  • AIM

    766.85
    -1.18 (-0.15%)
     
  • GBP/EUR

    1.1840
    +0.0003 (+0.03%)
     
  • GBP/USD

    1.2663
    -0.0023 (-0.18%)
     
  • Bitcoin GBP

    48,491.23
    +250.23 (+0.52%)
     
  • CMC Crypto 200

    1,276.18
    -7.60 (-0.59%)
     
  • S&P 500

    5,469.30
    +21.43 (+0.39%)
     
  • DOW

    39,112.16
    -299.05 (-0.76%)
     
  • CRUDE OIL

    81.29
    +0.46 (+0.57%)
     
  • GOLD FUTURES

    2,326.50
    -4.30 (-0.18%)
     
  • NIKKEI 225

    39,667.07
    +493.92 (+1.26%)
     
  • HANG SENG

    18,089.93
    +17.03 (+0.09%)
     
  • DAX

    18,134.48
    -43.14 (-0.24%)
     
  • CAC 40

    7,595.60
    -66.70 (-0.87%)
     

Merus Clears Wall Street's Bar With Cancer Data

Merus Clears Wall Street's Bar With Cancer Data

Merus appears to have cleared the bar set by Wall Street for its highly watched cancer-treatment candidate. The company posts an abstract for its head and neck cancer treatment on Thursday, boasting a 60% response rate and one complete response in a pool of 10 evaluable patients. William Blair analysts say in a research note that the early dataset is a clear encouraging sign on the potential treatment's efficacy.